High-energy photons and high-energy protons are very different in the ways they interact with matter. These differences lead to distinct advantages of protons over photons for treatment of cancer. Some aspects of proton interactions with tissue that make this modality superior for treating cancer are: (i) Initially, the protons lose energy very slowly as they enter the body; this results in a low entrance dose and low doses to the normal tissues proximal to the tumor. (ii) Near the end of range, protons lose energy very rapidly and deposit all their energy over a very small volume before they come to rest. This is the Bragg peak, a property that results in delivery of the maximum dose to the tumor. (iii) Beyond the Bragg peak, the energy deposited by the protons is zero; no dose is received by normal tissues distal to the tumor. Therefore, protons deliver their maximum dose to the tumor, a low dose to normal structures proximal to the tumor, and no dose to the normal structures beyond the tumor, ideal properties of a radiation modality to treat cancer. One distinct advantage of protons over photons is the ease with which the tumor target can be irradiated conformably to a high dose, and at the same time the normal structures in the vicinity of the tumor can be protected conformably from that high dose. Given the same dose to the tumor via photons and protons, protons inherently deliver less integral dose and, thus, lead to fewer normal-tissue complications. In addition, proton interactions also offer distinct radiobiological advantages over photons. Superior physical and radiobiological proton interactions lead naturally to the concepts of dose escalation and hypofractionation. The superiority of treatment delivery with protons as contrasted with photons is demonstrated by treatment plans.
Introduction
Radiation therapy is one of the accepted primary treatments for cancer. It may be used as sole treatment or, as is common these days, in combination with other modalities such as surgery and chemotherapy. About 50 percent of all cancer patients receive some form of radiation, in combination with another modality or by itself.
At present, most radiation therapy is delivered by means of high-energy photons -I use the terms photons, X rays, and gamma rays interchangeably. Electrons are used also, mainly to treat superficial tumors and in other applications where deep penetration of radiation is not needed. Heavier charged particles -the ions of hydrogen, helium, carbon, and other nuclei -are being used increasingly, especially protons, which have a clinical history that now spans more than half a century. Robert R. Wilson proposed their medical application in 1946 (1), and such applications first appeared in the 1950s to 1960s (2-5).
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Technology in Cancer Research & Treatment, Volume 6, Number 4 Supplement, August 2007 can kill any tumor cell or normal cell, in fact, if the dose is high enough. It is generally true that the higher the dose to the tumor, the greater is the likelihood of tumor control, and the lower the dose to normal cells, the lesser is the likelihood of complications and side effects. Accomplishing both goals simultaneously is the crux of radiation therapy. We want to give a high dose to tumor cells, which means we want to cause maximum tumor cell kill so that tumor cells do not proliferate. Our objective is to achieve tumor control, but at the same time we want to minimize the dose to the normal surrounding tissue so as to minimize complications. We want to maintain viability and function; if one cures prostate cancer and the patient loses rectal function or bladder function, for example, quality of life suffers. The physician desires to prolong life, but also desires to maintain the quality of life. These are the two goals: effective disease control and minimal side effects.
One of the crucial tools in helping radiation oncologists to attain these goals is improved imaging, and the most important of these to appear in the last 30 years is, in my opinion, computed tomography (CT). CT revolutionized radiation therapy. Actually, CT revolutionized diagnostic radiology and medicine as a whole. Magnetic resonance imaging (MRI), positron emission tomography (PET), and other modalities have appeared since, but CT was the major breakthrough in helping the radiation oncologist to visualize the tumor and its extensions, and also to visualize the dose distributions. Treatment planning algorithms developed subsequently, thanks to CT and computer-assisted planning systems. CT provides physicians and medical physicists with three-dimensional visualization of the tumor and the critical structures at risk.
It also tells us the properties of tissue, which are needed to predict dose distributions. CT and its sister modalities provide unprecedented, noninvasive access into the human body; essentially, the therapist can simulate everything about the patient before the patient is actually treated. In a very real sense, it was the availability of CT and computer-assisted planning systems, along with the computers to control a highly complex accelerator and beam-delivery system, that made it possible for Loma Linda University Medical Center (LLUMC) to pioneer hospital-based proton radiation treatment (6) . Once it became possible to identify and visualize the conformation of a tumor volume, and to plan treatments to deliver a conformal dose to that volume, it became feasible to plan and develop a highly conformal treatment modality, such as proton radiation therapy, for a hospital environment.
Proton Physics in Relation to Patient Treatment
High-energy protons have ideal properties for radiation therapy. Those properties can be subdivided into two major areas: radiobiological behavior and physical dose distributions, or physical controllability. This paper is concerned with the second aspect, but a few words are in order about the first.
A proton beam leaves a relatively sparse track of ionization events as it traverses tissue. The superiority of the proton ionization events in tissue arises from the fact that such events become densely packed as the proton beam proceeds toward its end of range. This microdosimetric quality of energy deposition renders a slightly higher radiobiological effectiveness (RBE) to proton beams. For clinical practice, an RBE value of 1.1 has been accepted based on earlier work on . Note that relatively little energy is deposited until the single beam nears its end of range, energy deposition then rises sharply, and peaks around 340 mm, then falls off rapidly to zero around 350 mm. This burst of energy deposition near the end of the range of a proton beam is called the Bragg peak. In clinical practice the Bragg peak is often "spread out" so as to encompass the tumor, but the overall energy deposition pattern is still the same: relatively little dose is deposited until the beam reaches the target, maximum energy is deposited in the target, and no radiation is deposited beyond the target. RBE of proton beams (7-9). Dose prescriptions for proton therapy are scaled by the RBE of the high-energy protons. Proton doses are prescribed in terms of cobalt gray equivalent (CGE), which is to say, the corresponding dose in terms of photons would be 1.1 times that of the physical proton dose. Essentially, to deliver the same CGE, we administer less of a proton dose. Based on the relatively sparse track of the ionization events caused by a proton beam along most of the beam path in tissue, however, a proton beam, for all practical matters, is considered low linear energy transfer (LET) radiation. The fact that protons are considered low-LET radiation means that all the clinical experience we had with photons -prescribed doses and fractionation schedules, for example -is also relevant to proton therapy.
The dosimetric superiority of high-energy proton beams for proton therapy results from the way in which protons interact with tissue. Protons interact with matter by continuous slowing down as result of Coulomb collisions with electrons and nuclei; by bremsstrahlung radiation loss; and by nuclear interactions. Of these, energy loss by bremsstrahlung interaction at clinically relevant proton energies (up to 250 MeV) can be ignored. Details of these interactions are not relevant to the present discussion, but these interactions have been studied thoroughly and are well understood (10, 11). Here we will examine the consequences of these interactions relevant to proton therapy.
One physical property that is very useful for treating patients is that high-energy protons, at a given energy, have a welldefined range, and beyond their range they deposit no energy. This means that once we know the distal depth of a tumor, we can choose the right proton energy to irradiate that tumor. By modulating the energy of the beam exiting the accelerator, we can stop a proton beam at any desired depth in tissue. Tissues distal to that depth receive no irradiation.
The manner in which protons deposit energy also contributes to their effectiveness in radiation therapy. Initially they lose energy very slowly; relatively little energy is deposited in tissues between the body surface and the target volume. Toward the end of their range, however, these particles lose energy rapidly. They deposit virtually all their energy over a very small volume before they come to rest. This is the Bragg peak (Fig. 1) . A photon beam, on the other hand, begins ionizing cells as soon as it enters the body. The highest dose deposition with a photon beam occurs only a few centimeters below the surface. Beyond this point of maximum dose deposition, a photon beam deposits energy in a near-exponentially decaying manner as it passes through the region proximal to the target, through the target tissue, and so on to the tissues beyond ( Fig. 2) (12) . This manner of energy deposition will always deposit dose beyond the target, and have a finite probability that some dose will exit on the other side of the patient.
This nature of interactions poses serious problems in photon therapy, and a great deal of effort goes into working around the implications of these interactions in photon therapy. Even the best efforts, including the development of intensity-modulated radiation therapy (IMRT), cannot completely overcome the fact that the best conformal dose to the tumor, with photon therapy, will still place a large volume of the normal tissue in a low-dose bath. Essentially, we are fighting with the intrinsic properties of the photon, a mass-less and charge-less particle, to deliver a conformal dose to the tumor.
The implications for conformability arising from the intrinsic physical properties of a high-energy proton beam are obvious, as Robert Wilson observed in 1946 (1) . Most of the ionizing energy can be deposited in the target volume; relatively little of it is deposited upstream of the target, and none is deposited downstream of the target. Here, in sharp contrast to a photon beam, we are working with the intrinsic properties of the proton interactions to deliver a conformal irradiation dose to the tumor. The early appreciation of protons for managing difficult-to-treat presentations, such as choroidal melanomas and tumors abutting the spinal cord, arose from these properties. Our experience at LLUMC has shown that protons are ideal for a great many other presentations as well (13). For most of these presentations, the target volume is larger than that encompassed by the Bragg peak of a single proton beam.
To treat those conditions, we "spread out" the Bragg peak by modulating the energy of the beam. This process raises the entrance dose at a given portal, but the entrance energy is nonetheless still much lower than is the case from even a high-energy photon beam (Fig. 2) .
One of the most appealing aspects of protons for therapy is the reduced volume integral dose they make possible; i.e., the total volume of tissues receiving radiation outside the target volume is significantly less with protons (Fig. 2) . Complications and side effects tend to occur less often, or be less severe, with protons than with photons because fewer normal tissues are receiving the radiation doses that cause such sequelae.
Delivering Conformal Proton Therapy
At present, all proton treatments at LLUMC are delivered by means of passive scattering. A scanning beam is in development and is expected to be operational in the near future, but even so, many treatments are still expected to be performed by the passive scattering method.
A cadre of beam-shaping devices is used to conform the proton beam to the patient's target volume (Fig. 3) . These work in tandem with the prescribed beam energy, which is set according to the depth of penetration desired. Among the beamshaping devices, an aperture is created for each treatment portal and is shaped to conform the tumor dose in the dimension lateral to the beam direction. A compensator bolus controls penetration of the beam, and in essence, conforms the dose in the distal direction (Fig. 4) . A modulation wheel spreads the Bragg peak to accommodate the extent of the tumor along the beam direction; i.e., the modulation wheel helps conform the dose in the proximal side of the tumor. Sets of modulation wheels are prefabricated, and the appropriate modulation wheel for a given portal is selected by the treatment planning system. Apertures and boluses are custom designed for each portal of every patient; the designs for these devices, again, are generated by the treatment planning system. With the aid of these devices, we can, in principle, deliver a three-di- The compensator bolus compensates for the density and thickness variations along the beam path en route to the target volume. A high-density structure in the beam path upstream of the target will result in the thinner bolus material, but a thin section of the target or a critical structure distally adjacent to the target will result in a thick bolus, as indicated in this figure. 
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Figure 5:
Comparison of typical four-field box techniques for treating prostate cancer. Note that although X rays (left) deliver the desired dose to the target, they also irradiate a much larger volume of normal tissue to a relatively high dose, a fact that has been proved to correlate with higher normal-tissue complications. By comparison, a four-field proton treatment (right) irradiates the target uniformly to the desired dose but at the same time delivers much less dose to the normal tissue. mensional conformal dose to a tumor with just one proton portal. Clinical constraints, such as location and extent of the tumor and the surrounding critical structures, often require more than one proton portal to deliver a conformal dose to the tumor and avoid unnecessary dose to the surrounding structures, but in general, proton therapy requires far fewer portals than does photon therapy. Thus, for the same tumor dose with protons or photons, protons inherently expose much less volume of the normal tissues to unwanted radiation.
Several clinical proton energies are used at Loma Linda (Table I ). With them, we can treat almost any tumor anywhere in the human body. We have variable energy capability, but have learned that the typical energies, used in concert with beam-shaping devices and materials, satisfy most treatment requirements.
All patients at Loma Linda, with tumors below the head and neck line, are treated in a whole-body pod that ensures wholebody immobilization. Patients being treated for tumors above the neck are fitted with a mask or may use a vacuum-assisted bite block. Sometimes the latter two are combined.
Discussion
The high degree of conformability made possible by protons opens up many possibilities for delivering high radiation doses to circumscribed, irregular volumes while largely sparing normal tissues, even those in close proximity to the targeted tissues. The ability to deliver a high, conformal dose deep into the patient's body is illustrated dramatically when one compares a dose distribution from a conventional four-port treatment set-up for prostate cancer with a similar arrangement for protons (Fig. 5) .
A protocol for treating breast cancer with protons is underway at Loma Linda (14). We are not treating the whole breast, as is commonly done following lumpectomy or partial breast resection, but treat a smaller volume around the post-operative bed. One of the goals of the effort is to deliver the needed dose to the breast tissue while sparing structures such as the heart, lungs, and the contralateral breast. Protons allow for this outcome more readily than can be accomplished with X rays (Fig. 6 ).
Proton radiation has long been known for its effectiveness in difficult-to-treat situations. Figure 7 shows two proton patch field combinations for treating a tumor that is wrapped around the spinal cord. The patient is treated with each combination on alternate days. The goal is to deliver a full dose to the tumor and spare both kidneys and the spinal cord, a task that can be accomplished easily with simple isocentric proton treatment. Both fields of each patch combination can be treated at one session, by moving the gantry from one side to the other. This is one illustration of the power of this modality.
Another example wherein protons can deliver a far superior treatment compared to photons is shown in Figure 8 . Here we show photon and proton dose distributions on a 3-yearold child with meduloblastoma. The goal is to irradiate the entire craniospinal axis and posterior fossa. Note the substantial reduction in dose to the vertebral bodies, and virtual elimination of exit dose through the thorax, abdomen, and pelvis with proton treatment. All of the child's critical growing structures are avoided with proton treatment.
Proton therapy is used to treat more than 50 different anatomic sites at Loma Linda. This may be surprising to some, who tend to associate proton radiation treatment at LLUMC with cancer of the prostate. Patients with prostate cancer do account for about 65% of the cases seen at Loma Linda, but that owes more to the prevalence of the disease -the most common in men -than to any limitation of proton radiation therapy. As time passes and technological enhancements are brought on line at LLUMC, such as a scanning beam that is now under development, protons will be used for an even wider variety of cancers. The treatment protocol for breast cancer, for example, is the likely forerunner of a major shift in the proportions of patients and cancer types treated at Loma Linda.
Proton therapy has clear advantages in terms of conformal dose delivery to tumors and conformal avoidance of normal structures. It is now an established form of radiation therapy. The concept that it is a financially and logistically viable component of a hospital operation has long been proved by the LLUMC experience. Its future is bright: active beam scanning, intensity-modulated proton therapy (IMPT), and biology-based treatment planning are all imminent. LLUMC will continue to play a leading role in realizing the advantages inherent in this radiotherapeutic modality.
